BioCentury | Jul 24, 2018
Distillery Techniques

Assays and screens

...arginine and serine rich coiled-coil 2 (RSRC2); and far upstream element binding protein 1 (FUBP1; FBP...
...email: pnigrovic@bwh.harvard.edu Claire Quang Arginine and serine rich coiled-coil 2 (RSRC2) Far upstream element binding protein 1 (FUBP1) (FBP) Recombination...
BioCentury | Jul 11, 2016
Clinical News

Nelipepimut-S: Phase III discontinued

...see BioCentury, Jan. 20, 2014). Galena’s most advanced program after NeuVax is GALE-301 . The folate binding protein-E39 (FBP)...
BioCentury | Jun 30, 2016
Clinical News

Galena plummets after halting NeuVax study

...update on its programs. Behind NeuVax, the company's most advanced program is GALE-301 , a folate binding protein-E39 (FBP)...
BioCentury | May 2, 2016
Clinical News

FBP vaccine: Additional Phase IIa data

...NASDAQ:GALE), Portland, Ore. Product: FBP vaccine ( GALE-301 ) Business: Cancer Molecular target: Folate binding protein-E39 (FBP) Description: Folate binding protein-E39 (FBP)...
BioCentury | May 2, 2016
Clinical News

GALE-302: Additional Phase IIa data

...vaccine-induced T cells. To avoid this, the company said it developed GALE-302. GALE-301 is a folate binding protein-E39 (FBP)...
...Portland, Ore. Product: GALE-302 (formerly J65 ) Business: Cancer Molecular target: NA Description: Attenuated folate binding protein-E39’ (FBP...
BioCentury | Jun 8, 2015
Clinical News

FBP vaccine: Additional Phase IIa data

...NASDAQ:GALE), Portland, Ore. Product: FBP vaccine ( GALE-301 ) Business: Cancer Molecular target: Folate binding protein-E39 (FBP) Description: Folate binding protein-E39 (FBP)...
BioCentury | Nov 17, 2014
Clinical News

FBP vaccine: Preliminary Phase IIa data

...NASDAQ:GALE), Portland, Ore. Product: FBP vaccine ( GALE-301 ) Business: Cancer Molecular target: Folate binding protein-E39 (FBP) Description: Folate binding protein-E39 (FBP)...
BioCentury | Aug 18, 2014
Clinical News

FBP vaccine: Preliminary Phase I data

...NASDAQ:GALE), Portland, Ore. Product: FBP vaccine ( GALE-301 ) Business: Cancer Molecular target: Folate binding protein-E39 (FBP) Description: Folate binding protein-E39 (FBP)...
BioCentury | Jul 14, 2014
Clinical News

FBP vaccine: Completed Phase IIa enrollment

...NASDAQ:GALE), Portland, Ore. Product: FBP vaccine ( GALE-301 ) Business: Cancer Molecular target: Folate binding protein-E39 (FBP) Description: Folate binding protein-E39 (FBP)...
BioCentury | Jan 13, 2014
Clinical News

GALE-301: Phase II started

...NASDAQ:GALE), Portland, Ore. Product: GALE-301 (formerly FBP vaccine ) Business: Cancer Molecular target: Folate binding protein-E39 (FBP) Description: Folate binding protein-E39 (FBP)...
Items per page:
1 - 10 of 22